Drugs / AERAS-422
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01340820 | Dec 2010 → Feb 2012 | tuberculosis | Aeras | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AERAS-422 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01340820 ↗ |
| Modality | Vaccine | “recombinant BCG vaccine AERAS-422” PMID 27322481 ↗ Apr 2016 |
| Route | Other | “single intradermal dose of AERAS-422” PMID 27322481 ↗ Apr 2016 |